BioSpace News Archive

Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market opens.

Sagimet Biosciences Inc. announced the commencement of an underwritten public offering of 9,000,000 shares of its Series A common stock.

SAB Biotherapeutics, Inc. announced that it received notice from The Nasdaq Stock Market LLC on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on the Nasdaq Capital Market.

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first pediatric patient has been dosed in clinical trial with its second generation pan-TRK inhibitor zurletrectinib at Sun Yat-sen University Cancer Center.

HD Immune GmbH announces commencement of operations by its two founders Dr. Stefan Bartl and Dr. Lionel Wightman.

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic diseases, today announced positive interim results from the first four cohorts of a Phase 1 clinical trial of oral ecnoglutide (XW004).

Harbour BioMed announced that the Company has been granted the clearance of Investigational New Drug from the Food and Drug Administration of the United States to initiate the first-in-human clinical trial in the U.S. for bispecific antibody HBM9027.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) for the Company’s product candidate aerosolized 4D-710 for treatment of cystic fibrosis (CF) lung disease.

ProPhase Labs, Inc. announces significant progress at Pharmaloz Manufacturing, Inc., its wholly owned subsidiary.

CereVasc, Inc. announced that data from its clinical studies in the United States and Argentina, examining the use of its eShunt System to treat communicating hydrocephalus, was presented at the ABC WIN Seminar in Val d’Isere.